Introduction
Apoptosis is a special type of programmed cell death that plays a crucial role in morphogenesis and tissue homeostasis. The major components of the apoptotic machinery are highly conserved during the course of evolution, underlying the fundamental importance of this phenomenon (Vaux and Korsmeyer, 1999) . The key effector molecules of apoptosis are the caspases (cysteine aspartate specific proteases), which cleave hundreds of substrates to bring about the typical apoptotic morphology (Fischer et al, 2003) . Apoptosis is activated by two major pathways namely the intrinsic or the mitochondria-mediated and the extrinsic or death receptor-mediated pathways. Depending on cell type the extrinsic pathway is also dependent on the mitochondrial pathway to induce apoptosis (Scaffidi et al, 1998) . Mitochondria respond to several death stimuli by releasing proapoptogenic factors such as cytochrome c and Smac/ DIABLO to the cytosol, which leads to the activation of caspases and apoptosis.
Bacterial pathogens profoundly modulate host cell apoptosis to achieve successful infection (Weinrauch and Zychlinsky, 1999) . The plethora of bacterial proteins inducing apoptosis include the pore forming alpha toxin from Staphylococcus aureus, listeriolysin O from Listeria monocytogenes, VacA from Helicobacter pylori and PorB from Neisseria gonorrhoeae. Indeed, mitochondria have emerged as a target for modulating host cell apoptosis by bacterial and viral pathogens (Müller and Rudel, 2001 ). We have previously shown that PorB from Ngo translocates to host cell mitochondria to induce mitochondrial membrane potential (MMP) loss and cytochrome c release to effect apoptosis (Mü ller et al, 2000) .
The genus Neisseria comprises of the human pathogenic species N. gonorrhoeae and N. meningitidis, which cause gonorrhea and meningitis, respectively. The initial contact with the host takes place at the epithelia, where a strong association of the pathogen to the cells is brought about by pili and Opa proteins (Naumann et al, 1999) . Attachment to epithelia leads to the transfer of the outer membrane porin PorB to the host cell cytoplasmic membranes (Weel and van Putten, 1991; Rudel et al, 1996) and the mitochondria (Massari et al, 2000; Mü ller et al, 2000) . Studies in yeast revealed that the import of PorB to mitochondria is dependent on the host mitochondrial import machinery and as in the bacterial outer membrane, translocated PorB can form trimers and multimers at the mitochondrial outer membrane (Mü ller et al, 2002) . Although purified PorB induces membrane potential loss and cytochrome c release in intact cells and in isolated mitochondria, transfected PorB did not induce cytochrome c release despite mitochondrial localization and loss of membrane potential (Mü ller et al, 2002) . This suggests that there may be a second signal required to induce cytochrome c release during infection (Müller et al, 2002) .
The release of proapoptotic proteins from the mitochondria during apoptosis is primarily mediated by the mitochondrial outer membrane permeabilization (MOMP). The permeabilization of the mitochondrial outer membrane is mainly effected by the multimerization of pore-forming socalled 'multidomain' proapoptotic family members Bax and Bak, which are activated by the members of the BH3 only family (Korsmeyer et al, 2000) . Recent evidence has shown that Bax and Bak can function in a redundant fashion to release cytochrome c in response to various apoptosis inducers (Wei et al, 2001) . Unlike Bax, Bak resides in the mitochondrial outer membrane and remains inactive by the direct interaction with antiapoptotic Bcl-2 family members like Mcl-1 or Bcl-X L . On the onset of apoptosis, Bak is activated either by displacement and/or degradation of Mcl-1 by the BH3 only members or p53 to cause cytochrome c release and apoptosis (Mihara et al, 2003; Chipuk et al, 2004; Leu et al, 2004) .
Here we show that the multidomain proapoptotic proteins Bak and Bax are activated sequentially during Ngo-and cisplatin-induced apoptosis. Bak activation precedes Bax activation to release cytochrome c from the mitochondria. Activation of Bax is Bak and caspase-9 dependent and is obligatory for effector caspase activation. Consistently, silencing of either Bak or Bax renders HeLa cells resistant to Ngo-and cisplatin-but not TNF/CHX-induced apoptosis, suggesting distinct roles for Bax and Bak during Ngo infection and DNA damage-induced apoptosis.
Results

Loss of mitochondrial membrane potential or cytochrome c release during Ngo infection is independent of caspases
To understand if Ngo infection-mediated loss of MMP is caspase-dependent, we checked if pretreatment of cells with zVAD-fmk (zVAD), a broad-spectrum caspase inhibitor, has any influence on Ngo-induced MMP loss. To perform these experiments, we first checked if pretreatment of cells with 50 mM of zVAD could inhibit caspase activity after induction of apoptosis with various inducers. As expected, 50 mM of zVAD could effectively inhibit Ngo-, cisplatin-and TNFa and cycloheximide (TNFa/CHX)-induced caspase 3/7 activity in HeLa cells (Supplementary Figure S1 ). These data suggested that zVAD is indeed a potent inhibitor of caspases in these cells irrespective of the inducer and length of apoptosis induction. HeLa cells infected with Ngo strain VPI or treated with TNFa/CHX underwent apoptosis in a zVAD-sensitive manner ( Figure 1A ). However, zVAD had no significant effect on infection-induced MMP loss as measured by TMRE staining ( Figure 1B ), indicating that MMP loss occurred in infected cells independent of caspase activity. To check if cytochrome c was still released from the mitochondria of the cells pretreated with zVAD upon Ngo infection, we performed immunofluorescence analysis of control, infected and infected zVAD-treated cells at 15 h postinfection, the time point at which most of the infected cells undergo apoptosis. Inhibition of caspases failed to prevent MMP loss or cytochrome c release ( Figure 1C and D) . Immunoblot analyses revealed that cytochrome c is released to the cytosol during Ngo infection in the presence of zVAD (Figure 1E and F) . This suggests that during Ngo infection, cytochrome c release is a caspase-independent event.
Activation of Bax but not Bak needs active caspases during Ngo-and cisplatin-induced apoptosis
Release of cytochrome c is primarily effected by MOMP, which is mediated by the activation of proapoptotic Bcl-2 family members Bak and Bax. Upon activation they undergo conformational changes, which can be monitored by conformation-specific antibodies. In order to test whether Ngo activates Bak and Bax, infected cells were stained with antiactive Bak and antiactive Bax antiserum and analyzed by fluorescence activated cell sorting (FACS) (Figure 2A and B). These analyzes clearly showed that Bak and Bax are activated in infected cells as evidenced by a shift in FL-1 channel. Moreover, the results were further confirmed by immunoprecipitation experiments showing that infectioninduced Bak and Bax activation were similarly efficient as TNFa/CHX treatment ( Figure 2C ).
Since Bak and Bax may be activated by caspase-dependent or -independent pathways, we tested the involvement of caspases in the infection-induced Bak and Bax activation. HeLa cells were infected or pretreated with zVAD before infection and 15 h later active Bak or Bax were precipitated. Surprisingly, Bak, but not Bax was precipitated with conformation-specific antibodies in the presence of the pan-caspase inhibitor zVAD ( Figure 2C ). The caspase-independent and -dependent activation of Bak and Bax, respectively, was also confirmed by FACS analysis (Figure 2A) . Consistent with the zVAD-dependent activation, translocation of Bax to mitochondria was impaired in the presence of zVAD upon Ngo infection (Supplementary Figure S2) . The requirement of active caspases for Bax but not for Bak is an intriguing observation, as Bax and Bak have been shown to be activated in a similar manner. To check if the observed phenomenon is specific to Ngo-induced apoptosis, we tested if blocking caspases has any influence in the activation of Bax during cisplatin-induced apoptosis. Interestingly, pretreatment of cells with zVAD blocked Bax but not Bak activation during cisplatin-induced apoptosis ( Figure 2C ). As previously observed for infected cells, translocation of Bax to mitochondria was impaired in the presence of zVAD upon cisplatin treatment (Supplementary Figure S2) . Finally, to confirm if the observed phenotype is not confined to a single-cell type, we have performed these experiments in a second epithelial cell line, HEp-2, derived from human larynx carcinoma. As expected, zVAD inhibited Bax but not Bak activation when treated with cisplatin as observed in HeLa cells (Supplementary Figure S3) . These data showed that Bak and Bax are activated by zVAD-independent and -dependent mechanisms, respectively, upon Ngo-infection and cisplatin treatment in these cells.
As cytochrome c is released from the mitochondria despite zVAD treatment during Ngo infection, we checked if cytochrome c release during cisplatin induction is also independent of active caspases. Interestingly, cytochrome c is still released upon cisplatin treatment despite zVAD treatment ( Figure 2D ). These data suggested that cytochrome c is released in these cells even when caspases were inhibited during Ngo-and cisplatin-mediated apoptosis.
Bak is required for Ngo-and cisplatin-induced Bax activation
The differential requirement for caspases could either mean that Bak and Bax are activated simultaneously by different pathways or sequentially by the same initial stimulus. Time course experiments with Ngo revealed Bak being activated between 4 and 6 h postinfection and Bax between 6 and 8 h postinfection (Supplementary Figure S4) suggesting a sequential rather than a parallel activation of Bak and Bax. To investigate whether Bax activation depends on active Bak, we designed short-interfering RNAs (siRNAs) for transient silencing of bak and bax. In addition, expression vectors for short hairpin RNAs (shRNAs) were introduced into HeLa cells by lentiviral transduction to permanently silence the expression of Bak and Bax by RNA interference (RNAi). Both, siRNAs and shRNAs reduced the homologous mRNA by more than 80% (Supplementary Figure S5) . Moreover, a clear reduction specific antibody. Ngo infection and cisplatin treatment failed to activate Bax in the absence of Bak ( Figure 3D and E) indicating that Bak is required for the infection-and cisplatininduced activation of Bax. Treatment of HeLa-shBak with TNFa/CHX induced a conformational change in Bax ( Figure 3F ) demonstrating that TNF-receptor-induced activation of Bax is independent of Bak in these cells.
Bak and Bax are required for infection and cisplatininduced apoptosis
Previous studies with knockout mice revealed that Bak and Bax exert very similar functions in most of the stress-induced apoptotic pathways and can functionally substitute each other (Wei et al, 2001) . To test whether Ngo induces apoptosis via either Bak or Bax, we silenced their expression and analyzed infection-induced apoptosis by TUNEL analysis. The fraction of apoptotic cells was reduced from 29% in the control transfected cells to 7% (Po0.001) in Bak-silenced and to 16% (Po0.005) in Bax-silenced cells ( Figure 4A ). Consistently, 27% of the infected cells transfected with control siRNA exhibited an increased caspase activity indicative of induction of apoptosis ( Figure 4B) . Surprisingly, the fraction of apoptotic cells was significantly reduced in cells with reduced Bak expression (11%; Po0.001) but also in siBax transfected cells (18%; Po0.001). To confirm these results, cleaved caspase-3 was detected by immunoblot analysis. Infection induced a strong activation of caspase-3 in control-transfected cells ( Figure 4C ) whereas cleaved caspases-3 was strongly reduced or not detectable in infected cells with reduced expression of Bax or Bak or both, respectively ( Figure 4C ). Similar results were obtained when the Bak-or Bax-silenced cells were induced to apoptosis with cisplatin. Depletion of either Bak or Bax reduced the apoptotic response and the activation of caspase-3 ( Figure 4D and E). In contrast, neither Bak nor Bax were required for TNFa/CHX-induced apoptosis and effector caspase activation ( Figure 4D and E) ruling out unspecific inhibition of caspase-3 activation due to experimental settings. Finally, HeLa cells depleted of both, Bax and Bak by siRNAs (Supplementary Figure S6A) resisted Ngo-and cisplatin-, but not TNFa/CHX-induced apoptosis ( Figure 4C and Supplementary Figure S6B ). These data suggested that Bak and Bax are functionally non-redundant and are both required for infection-and cisplatin-induced apoptosis.
Bak-dependent release of cytochrome c during Ngoand cisplatin-induced apoptosis
The requirement of both Bak and Bax during cisplatin-and Ngo-induced apoptosis suggested that both Bax and Bak have distinct roles during stress-induced apoptosis. One of the key events during stress-induced apoptosis is the MOMP and the release of cytochrome c to trigger the formation of the apoptosome. As cytochrome c is still released in the absence of active Bax (zVAD treated cells), we hypothesized that the release of cytochrome c is primarily influenced by Bak in these cells. To test this hypothesis, we made use of the HeLa Figure 3B and C). Consistently both shBaxand shBak-expressing HeLa cells were profoundly resistant to cisplatin-induced apoptosis (Supplementary Figure S7A and B) reconfirming the distinct roles for Bak and Bax during stress-induced apoptosis. In addition, we have tested if shBax and shBak cells were resistant to other inducers of the intrinsic pathway of apoptosis. Interestingly, both shBak and shBax cells resisted brefeldin A-, staurosporine-and doxorubicin-induced apoptosis (Supplementary Figure S8) . To test for the specific role of Bak and Bax, control and shBak-and shBax-expressing cells were infected with Ngo or treated with cisplatin and the release of cytochrome c was monitored by immunofluorescence analysis (Figure 5A and B). To our surprise, cytochrome c release was blocked in the shBak but not in the shBax cells when infected with Ngo or induced with cisplatin suggesting the specific role of Bak in releasing cytochrome c during Ngo-and cisplatin-induced apoptosis ( Figure 5A and B) . To further confirm these observations, subcellular fractionation experiments were performed and the amounts of released cytochrome c was monitored by immunoblot analysis. Consistent with the immunofluorescence data, release of cytochrome c is abrogated in the shBak-cells but not in shBax-expressing cells upon Ngo infection or cisplatin treatment ( Figure 5C and D). These data suggested that Bak is specifically required to release cytochrome c from the mitochondria of these cells during Ngo-and cisplatin-induced apoptosis.
Caspase-9 is required to activate Bax
Release of cytochrome c to the cytosol triggers the formation of apoptosome where caspase-9 is recruited for activation.
As activation of Bax is caspase dependent, we tested if the silencing of caspase-9 can inhibit Bax activation. Therefore, we used siRNAs to silence the expression of caspase-9 in HeLa cells and checked for the activation of Bax upon Ngo infection. Indeed, Ngo infection activated only Bak but not Bax in caspase-9 silenced cells ( Figure 6A ). Bax activation was also abrogated upon Ngo infection when caspase-9 activity was inhibited by the caspase-9-specific chemical inhibitor LEHD-fmk ( Figure 6B ). As expected cisplatin treatment also failed to induce the activation of Bax in cells depleted of caspase-9 ( Figure 6C ), suggesting a role of caspase-9 in Bax activation. To further confirm the requirement of the apoptosome in activating Bax, we investigated the influence of Apaf-1, the adaptor protein responsible for the formation of the apoptosome complex activating caspase-9. HeLa cells depleted of Apaf-1 by RNAi were induced to apoptosis with Ngo or cisplatin. The efficiency of the knockdown was monitored by real-time PCR and immunoblot analysis (Supplementary Figure S9A and B). In line with our previous observations, loss of Apaf-1 caused resistance for both, Ngo-and cisplatin-induced apoptosis (data not shown). Apoptosis induction failed to activate Bax but still activated Bak in cells depleted of Apaf-1 ( Figure 6D and E) suggesting that apoptosome formation and activation of caspase-9 are obligatory for the activation of Bax during Ngo-and cisplatin-mediated apoptosis in these cells. (Wei et al, 2001 ). An unexpected finding of the infection-induced and also the DNA damage-induced apoptosis described here was the distinct roles for Bak and Bax. This is in contrast to many apoptosis-inducing drugs activating apoptotic pathways for which Bak and Bax were functionally redundant (Wei et al, 2001) . Interestingly, we found that Ngo infection and cisplatin treatment leads to the engagement of both, caspase-independent and caspasedependent pathways resulting in the activation of Bak and Bax, respectively. We observed that Bak not only preceded, but was also required for Bax activation in accordance with their function in the same signaling cascade, but in a hierarchical manner.
Although we currently do not know how Bak and Bax are activated during infection, a role for the BH3 only proteins is likely. Proapoptotic activity of BH3 only proteins is controlled by transcriptional and post-translational mechanisms (Bouillet and Strasser, 2002) . Control of Bad and Bik, for example, requires phosphorylation and dephosphorylation (Zha et al, 1996; Verma et al, 2001) whereas Bid activation involves cleavage by caspases or other proteases Luo et al, 1998; Deng et al, 2003) . It is thus possible that the initial activation of Bak requires signals elicited early during infection or as a consequence of increasing bacterial load similar to treatment of cells with cisplatin. These signals cause the displacement of Mcl-1, a member of the Bcl-2 family inhibiting apoptosis, from Bak (Willis et al, 2005) . Consistently, Mcl-1 co-precipitated with Bak in non-infected, but not in infected cells (Supplementary Figure S9) , suggesting an efficient displacement of Mcl-1 from Bak upon infection. Once Bak is active, cytochrome c is released and Bax is activated in a caspase-9-dependent fashion to activate effector caspases. Recent observations with the caspase-3 and -7 double knockout fibroblasts also revealed a caspase-dependent activation of Bax and release of cytochrome c from the mitochondria (Lakhani et al, 2006) . 
E
Figure 6 Caspase-9 is required to activate Bax. (A) Caspase-9 expression was silenced in infected or non-infected cells using siRNA and active Bak or Bax was precipitated as indicated. Knockdown of caspase-9 was validated using anticaspase-9 antibody. An influence of caspase-9 knockdown on the expression levels of Bak and Bax was excluded by additional analysis of the cell lysates using anti-Bak NT and anti-Bax NT antibodies. (B) Infected and non-infected cells were pretreated with the caspase-9 inhibitor LEHD-fmk and active Bax and Bak were precipitated as indicated. (C) The effect of caspase-9 knockdown on Bax activation upon cisplatin treatment was analysed as described before. The activation of Bax upon infection and cisplatin treatment was dependent on caspase-9. (D, E) Apaf-1 is required for the activation of Bax. Apaf-1 expression was silenced with siRNAs and active Bax and Bak were immunoprecipitated as indicated.
The mechanism by which cytochrome c is released from the mitochondria has been intensively debated (Green and Kroemer, 2004) . Two models have been proposed and experimental evidence exists for both. In the first model, a to-date undefined PT complex of the mitochondrial membranes is activated and leads to the loss of MMP. As a consequence, mitochondria swell causing the rupture of the outer membrane, release of cytochrome c and consequently apoptosis. However, the mitochondria of apoptotic cells remain not swollen in most of the cases including Ngo-induced apoptosis (data not shown). In the second model, MOMP is accomplished by formation of supra-molecular openings in the outer mitochondrial membrane promoted by activated Bax and cardiolipin in a manner inhibited by Bcl-X L (Kuwana et al, 2002) . During Ngo-and cisplatin-induced apoptosis, activation of Bak is obligatory for cytochrome c release as silencing of BAK abrogated cytochrome c release and apoptosis. However, release of cytochrome c alone is not enough to drive the cells to apoptosis as cells silenced for the expression of Bax are also resistant to apoptosis. This suggests that Bax maybe involved either directly or indirectly in releasing other proapoptotic factors from the mitochondria, which may promote effector caspase activation.
Although Bak is required for the release of cytochrome c, we detect no role of Bak in Ngo-induced MMP loss (data not shown). Depending on the inducer of apoptosis, MMP loss may precede or follow caspase activation. In fact, active caspases cleave mitochondrial substrates like the p75 subunit of the electron transport chain complex I causing loss of MMP (Ricci et al, 2004) . During Ngo-induced apoptosis, MMP loss occurs independent of Bak and caspases (Figure 1 and data not shown). This suggests that MMP loss is probably due to the targeting of PorB and the perforation of the inner mitochondrial membrane as loss of MMP is still evident in infected cells pretreated with zVAD ( Figure 1B-D) .
Induction of apoptosis may either support the infection or serve as a host defense strategy to eliminate the infected cell. Most importantly, pathogens often evolved unique ways to modulate the apoptotic program in host cells. Although these natural apoptosis pathways may have high therapeutic relevance, they are by far less well investigated than mechanisms underlying artificial, For example drug-induced apoptosis. Here we describe the molecular basis of naturally induced apoptosis by Ngo infection.
Materials and methods
Human cell culture and infection
HeLa cells (human cervix carcinoma), HEp-2 (human larynx carcinoma cell line) were grown in RPMI 1640 (Gibco) supplemented with 10% heat inactivated FCS in the presence of 5% CO 2 . Cells were seeded 24 h before infection, washed several times with RPMI without supplements. Infections were routinely performed at an multiplicity of infection (MOI) of 1 for 15 h. For inhibition of caspases, cells were preincubated with 50 mM zVAD-fmk (Bachem) for 15 min before infection/induction and throughout the respective experiment. 293T cells for the production of virus were grown in DMEM (Gibco) supplemented with 10% heat inactivated FCS under the same conditions.
Western blot
Cells were harvested in loading buffer (60 mM Tris-HCl (pH 8.0), 6% SDS, 10 mM DTT, 6% b-mercaptoethanol, 40% glycerol and 0.1% bromophenol blue) and proteins were separated on 12-15% SDS-polyacrylamide gels and then blotted onto PVDF membranes (Millipore). Membranes were blocked for 1 h in 3% bovine serum albumin in Tris-buffered saline (TBS, pH 7.5), 0.1% Tween and then incubated overnight with respective antibodies in 3% bovine serum albumin in TBS, 0.1% Tween. The blots were washed three times for 10 min in TBS/0.1% Tween, incubated for another hour with peroxidase-coupled secondary antibody (Amersham), and bound antibody was detected by enhanced chemiluminescence (Western lightning) on Hyperfilm ECL (Amersham) or in a luminescent image analyzer LAS-3000 (Fujifilm). Antibodies/antisera used in this study: anti-b-actin (Sigma); anti-Bax NT (Upstate); anti-Bax (BD Pharmingen); anti-Bak NT (Upstate); anti-cleaved caspase-3 (Cell Signalling); anti-Mcl-1 (BD Pharmingen), anti-Tom-20 (Sigma), anti-ATP synthase a (BD Pharmingen), anti-Cox II (Molecular Probes) and anti-Caspase-9 (Cell Signalling). Equal loading was routinely confirmed by appropriate loading controls using anti-bactin antibody (Sigma).
Fractionation of cells
To obtain mitochondria enriched fractions, HeLa cells were washed twice with ice-cold PBS, harvested and washed in M-Buffer (0.4 M sucrose, 50 mM Tris, 1 mM EGTA, 5 mM b-ME, 0.2% bovine serum albumin (BSA), 10 mM KH 2 PO 4 , pH 7.6). The cells were resuspended in M-Buffer and incubated for 20 min on ice. The cells were lysed using a Dounce homogenizer and the nuclei and debris were removed by centrifugation at 4000g for 1 min. The supernatant was carefully removed and the mitochondria containing heavy membranes were then obtained by centrifugation at 15 000g for 10 min. The cytoplasmic proteins contained in the supernatant were analyzed for cytochrome c by immunoblotting.
Subcellular fractionation experiments with the proteo-extraction kit (Merk Biosciences) following the manufacturers instructions. Fraction 1 is used as a cytosol and fraction 2 is used a mitochondria enriched fraction. The purity of cytosolic fractions was controlled by immunoblots using antibodies against mitochondrial marker proteins (COX II and ATPase Synthase a).
FACS analysis
Activation of Bak and Bax was measured by FACS analysis. Control and infected HeLa cells were harvested, washed with PBS (Gibco) and fixed in 2% PFA for 30 min at 41C. After an additional wash in PBS, cells were incubated in Buffer S (1% FCS, 1% Saponin in PBS) with 0.5 mg anti-Bax 6A7 (BD Pharmingen) or anti-Bak AB1 (Oncogene) for 30 min at 41C. Cells were washed with Buffer W (1% FCS in PBS) and stained in Buffer S with Cy2 conjugated antimouse or anti-rabbit secondary antibody (Jackson Immuno Research) for 30 min at 41C. Cells were washed twice with Buffer W before to FACS analysis.
For the analysis of MMP, cells were harvested by trypsinization and washed with PBS before staining with 100 nM TMRE (Molecular Probes) in growth media at 371C, 5% CO 2 for 30 min. After staining, cells were washed twice with PBS and immediately analyzed by FACS analysis.
Apoptosis assays
Control and infected cells were collected and washed twice with PBS and fixed with 70% ethanol at À201C for 30 min. Cells were pretreated with zVAD-fmk (Bachem) as indicated. After removing ethanol, the cell pellets were stained with Nicoletti buffer (0.1% Triton X-100, 50 mg/ml propidium iodide in PBS, pH 7,4) at room temperature in the dark for 20 min and measured by FACS analysis. Caspase-3 and -7 activities were measured by CaspACE assay. Control and infected cells were collected and stained with 10 mM CaspACE (Promega) in growth media at 371C, 5% CO 2 for 20 min. After staining, cells were washed twice with PBS and immediately subjected to FACS analysis. Unless otherwise mentioned cells were induced to apoptosis, with cisplatin at a final concentration of 60 mM for 15 h, Brefeldin A at a final concentration of 1.5 mg/ml for 35 h, staurosporine at 1.5 mM for 6 h and 4 mM of doxorubicin for 40 h. For TNFa-induced apoptosis cells were treated with 25 ng/ml TNFa together with 10 mg/ml cycloheximid for 5 h. The cells were fixed with 3% PFA as mentioned before and stained with Hoechst 33342 as mentioned below.
Immunoprecipitation
Cells were washed in PBS and lysed in Buffer P (150 mM NaCl, 10 mM HEPES, 1% CHAPS, pH 7.4) containing Complete Protease Inhibitor (Roche). Cleared lysates were incubated over night with mg of conformation specific anti-Bax 6A7 or anti-Bak Ab1 antibody in an overhead rotator at 41C. Protein G-sepharose (20 ml) (Amersham) was added and incubation was continued for 2 h. After extensive washing with Buffer P, the precipitates were boiled in sample buffer at 951C and the proteins were separated by SDS-PAGE. Western blots were performed using anti-Bax and anti-Bak antibodies (Upstate). For co-immunoprecipitation of Mcl-1 and Bak, control and infected cells were lysed in Buffer P and the lysates were cleared by centrifugation. Mcl-1 and Bak were immunoprecipitated with anti-Mcl-1 (BD Pharmingen) or anti-Bak (BD Pharmingen) antibodies, respectively, and detected by immunoblot.
RNA interference
HeLa cells were grown in 12-well plates for 24 h and then transfected with 1 mg of siRNA using RNAiFect transfection kit (Qiagen) according to the manufacturer's instructions. Efficiency of gene silencing was generally validated by real time PCR as previously described (Machuy et al, 2005) and by Western blot analysis 72 h post-transfection. Protein levels were routinely checked by Western blot analysis in experiments involving RNAi. The sequence targeted by siBax, siBak, siCaspase-9, siApaf-1 and siLuciferase are AAGGTGCCGGAACTGATCAGA, AAGCGAAGTC TTTGCCTTCTC, CAGTGACATCTTTGTGTCCTA, AAGAGCAGCTATG CTGATTAA and AACUUACGCUGAGUACUUCGA respectively.
shRNA oligonucleotides were annealed and cloned into the pLL3.7 or pLVTH-M vectors (Rubinson et al, 2003; Wiznerowicz and Trono, 2003) , which carry a GFP cassette for monitoring virus production and infection. The following sequences were targeted to silence Bax and BAK by shRNA expression: GCUCUGAGCAGAU CAUGAA and CCCAUUCACUACAGGUGAA, respectively. Virus carrying Bak shRNAs or Bax shRNAs were produced by transfecting 293T cells with pLL3.7 shBak or pLVTH-M shBax together with viral packaging vectors (psPAX2, pMD2G) by calcium phosphate transfection. Virus were harvested from the supernatant 48 h posttransfection and concentrated by ultracentrifugation at 25 000 r.p.m.
HeLa cells were infected with Bak shRNA or Bax shRNA containing virus. Three days postinfection, GFP positive cells were enriched by FACS sorting. Single clones of cells expressing GFP were lysed in sample buffer and the efficiency of gene silencing was checked by Western blot analysis as mentioned above. The cells transfected with the empty vector were used as control.
Immunofluorescence microscopy
Cells seeded on coverslips were infected for 15 h or treated with cisplatin for 20 h. Cells were fixed in 3.7% PFA sometimes followed by staining with 150 nM MitoTracker CMTMRos (M7510) (Molecular Probes). Fixed cells were permeabilized using 0.2% Triton X-100 and nonspecific binding was blocked by using 1% goat serum. Samples were stained using anticytochrome c (BD Pharmingen), anti-Tom-20 (Sigma) or anti-Bax-NT antibody (Upstate) followed by detection with fluorochrome-coupled secondary antibodies (Jackson Immuno Research). Samples were routinely costained with Hoechst 33342 to visualize DNA fragmentation and were analyzed under a Leica confocal microscope using TCS software or a Zeiss immunofluorescence microscope using ACT software.
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